Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: Relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease

Bone Marrow Transplantation

Volumn 21, Issue 6, 1998, Pages 597-605

  Gor, D ^a   Sabin, C ^a   Prentice, H G ^a   Vyas, N ^a   Man, S ^a   Griffiths, P D ^a   Emery, V C ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Ganciclovir; Quantitation; Replication; Viral load

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR;

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CYTOMEGALOVIRUS; LEUKEMIA; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCHOOL CHILD; SEROPREVALENCE; SOLID TUMOR; VIRUS LOAD;

EID: 0031884833     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701139     Document Type: Article

References (40)

1. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478-488.
2. Neiman PE, Reeves W, Ray G, et al. A prospective analysis interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts. J Infect Dis 1977; 136: 754-767.
3. Pillay D, Webster A, Prentice HG, Griffiths PD. Risk factors for viral reactivation following bone marrow transplantation. Ann Hematol 1992; 64 (Suppl A): 148-151.
4. Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990; 162: 373-380.
5. Meyers JD. Prevention and treatment of cytomegalovirus infection after marrow transplantation. Bone Marrow Transplant 1988: 3: 95-104.
6. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: a review of 10 years' experience. Rev Infect Dis 1982; 4: 1119-1132.
7. Webster A, Blizzard B, Pillay D, et al. Value of routine surveillance cultures for detection of CMV pneumonitis following bone marrow transplantation. Bone Marrow Transplant 1993; 12; 477-481.
8. Ehrnst A, Barkholt L, Brattstrom C et al. Detection of CMV-matrix pp65 antigen in leucocytes by immunofluorescence as a marker of CMV disease. J Med Virol 1993; 39: 118-124.
9. Jiwa NM, Van Gemert GW, Raap AK et al. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction. Transplantation 1989; 48: 72-76.
10. Einsele H, Steidle M, Vallbracht A et al. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 1991; 77: 1104-1110.
11. Einsele H, Ehninger G, Steidle M et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 1991; 338: 1170-1172.
12. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side-effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
13. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: the City of Hope-Stanford-Syntex CMV Study Group. New Engl J Med 1991; 324: 1005-1011.
14. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Engl J Med 1991; 325: 1601-1607.
15. Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
16. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118: 179-184.
17. Prentice HG, Gluckman E, Powles RL et al. Impact of longterm acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749-753.
18. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus-specific T cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
19. Stagno S, Reynolds DW, Tsiantos A et al. Comparative serial virologic and serologic studies of symptomatic and subclinical congenitally and natally acquired cytomegalovirus infections. J Infect Dis 1975; 132: 568-577.
20. Cope AV, Sabin C, Borroughs A et al. Inter-relationships between quantity of HCMV DNA in blood, donor/recipient serostatus and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176: 1484-1490.
21. Cope AV, Sweny P, Sabin C et al. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J Med Virol 1997; 52: 200-205.
22. Kuhn JE, Wendland T, Schafer P et al. Monitoring of renal allograft recipients by quantitation of human cytomegalovirus genomes in peripheral blood leukocytes. J Med Virol 1994; 44: 398-405.
23. Rasmussen L, Morris S, Zipeto D et al. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis 1995; 171: 177-182.
24. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238-241.
25. Rawal BK, Booth JC, Fernando S et al. Quantification of cytomegalovirus DNA in blood specimens from bone marrow transplant recipients by the polymerase chain reaction. J Virol Meth 1994; 47: 189-202.
26. Ljungman P, Aschan J, Azinge JN et al. Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. Br J Haematol 1993; 83: 118-124.
27. Link H, Battmer K, Stumme C. Cytomegalovirus infection in leucocytes after bone marrow transplantation demonstrated by mRNA in situ hybridization. Br J Haematol 1993; 85: 573-577.
28. Berry NJ, Grundy JE, Griffiths PD. An improved radioimmunoassay method for the detection of IgG antibodies against cytomegalovirus. J Virol Meth 1986; 13: 343-350.
29. Ljungman P, Plotkin SA. Workshop on CMV disease: definitions, clinical severity scores, and new syndromes. Scand J Infect Dis 1995; 99 (Suppl.): 87-89.
30. Kidd IM, Fox JC, Pillay D et al. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation 1993; 56: 867-871.
31. Gor D, Lee D, Griffiths PD, Emery VC. Detection of human cytomegalovirus polymerase chain reaction products using oligonucleotide probes directly conjugated to alkaline phosphatase. J Virol Meth 1996; 61: 145-150.
32. Fox JC, Griffiths PD, Emery VC. Quantification of human cytomegalovirus DNA using the polymerase chain reaction. J Gen Virol 1992; 73: 2405-2408.
33. Grob JB, Grundy JE, Prentice HG et al. Immune donors can protect marrow transplant recipients from severe cytomegalovirus infections. Lancet 1987; 1: 774-776.
34. Enright H, Haake R, Weisdorf D et al. Cytomegalovirus pneumonia after bone marrow transplantation: risk factors and response to therapy. Transplantation 1993; 55: 1339-1346.
35. Zhang LJ, Hanff P, Rutherford C et al. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis 1995; 171: 1002-1006.
36. Wimperis JZ, Brenner MK, Prentice HG et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1986; 1: 339-343.
37. Hongeng S, Krance R, Bowman LC et al. Outcomes of transplantation with matched-sibling and unrelated donor bone marrow in children with leukaemia. Lancet 1997; 350: 767-771.
38. Deane M, Gor D, McMahon E et al. Quantitation of HCMV viraemia in a case of transfusion related graft-versus-host disease with purine analogue treatment. Br J Haematol 1997; 99: 162-164.
39. + cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant 1994; 14 (suppl 4): S78-S84.
40. Krause H, Hebart H, Jahn G et al. Screening of CMV specific T-cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997; 19: 1111-1116.